Ulrike K. Buchwald

Ulrike K. Buchwald

Infectious Disease | Gastroenterology

2360 West Joppa Road, Joppa Concourse STE 205
Joppa Concourse STE 205
Lutherville, MD 21093

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.

Journal: Vaccines

Published: November 19, 2025

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192.

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192.

Journal: Vaccines

Published: September 29, 2025

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 25, 2025

Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. Vaccines 2024, 12, 974.

Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. Vaccines 2024, 12, 974.

Journal: Vaccines

Published: June 25, 2025

Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies.

Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies.

Journal: The Journal of infectious diseases

Published: June 04, 2025

Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116.

Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116.

Journal: Communications medicine

Published: May 01, 2025

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

Journal: Vaccines

Published: January 13, 2025

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.

Journal: Vaccines

Published: January 02, 2025

The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.

The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.

Journal: Vaccine

Published: November 14, 2024

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.

Journal: Expert review of vaccines

Published: October 22, 2024

Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.

Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.

Journal: Vaccines

Published: April 12, 2024

Anal dysplasia and anal cancer screening practices among liver transplant centers in the United States: Results of an online survey.

Anal dysplasia and anal cancer screening practices among liver transplant centers in the United States: Results of an online survey.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: April 01, 2024

Showing 1-12 of 57

Last Updated: 09/26/2026